

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Wednesday, June 11, 2025  
**Time:** 9:00 am Central Time  
**Location:** Zoom Teleconference  
**Institution:** Northwestern University, Chicago, IL  
**Principal Investigator:** Arjun Seth, MD  
**Protocol:** Cabaletta Bio Inc., CAB-201-004  
**NCT Number:** NCT06359041  
**Meeting Type:** Continuing Review of Protocol and Site  
**Title:** A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Generalized Myasthenia Gravis

### 1. Call to order:

The Meeting was called to order at 9:12 am Central Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present were four Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Approval of previous meeting minutes:

Minutes Approved - YES: 6                      NO: 0                      ABSTAIN: 0

### 7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

### 8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for CABA-201 since it consists of human cells modified with a lentiviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of CABA-201 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

### 9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6                      NO: 0                      ABSTAIN: 0

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Points of Discussion:**

1. The Committee noted that the Institution recently submitted updated photos of the water bath and transport container, labeled with a larger biohazard symbol.
2. The Committee noted that one of the Biological Safety Cabinets was removed from use for this study.
3. The Committee noted that IATA/DOT Shipping Training Certification will expire in June 2025.

### **11. Site requirements:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

### **12. Vote on the Site:**

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6

NO: 0

ABSTAIN: 0

**13. Advice to the Institution:** None.

**14. Meeting adjourned:** The meeting was adjourned at 9:16 am Central Time.